Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 12
Submit an article Journal homepage
2,279
Views
0
CrossRef citations to date
0
Altmetric
News & Views

DRUG FOCUS: Pharmacogenetic Studies Related to Cyclophosphamide-Based Therapy

Navin Pinto1 University of Chicago, 900 East 57th Street, Room 7100, Chicago, IL 60637, USAView further author information
,
Susan M Ludeman2 Albany College of Pharmacy & Health Sciences, NY, USAView further author information
&
M Eileen Dolan1 University of Chicago, 900 East 57th Street, Room 7100, Chicago, IL 60637, USACorrespondence[email protected]
View further author information
Pages 1897-1903 | Published online: 03 Dec 2009

Bibliography

  • Colvin OM : An overview of cyclophosphamide development and clinical applications.Curr. Pharm. Des.5(8) , 555–560 (1999).
  • Ludeman SM : The chemistry of the metabolites of cyclophosphamide.Curr. Pharm. Des.5(8) , 627–643 (1999).
  • Cox PJ : Cyclophosphamide cystitis – identification of acrolein as the causative agent.Biochem. Pharmacol.28(13) , 2045–2049 (1979).
  • Parekh HK , SladekNE: NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.Biochem. Pharmacol.46(6) , 1043–1052 (1993).
  • Hayes JD , PulfordDJ: The glutathione S-transferase supergene family: regulation of gst and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.Crit. Rev. Biochem. Mol. Biol.30(6) , 445–600 (1995).
  • Dirven HA , VenekampJC, van Ommen B, van Bladeren PJ: The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31p nuclear magnetic resonance spectroscopy. Chem. Biol. Interact.93(3) , 185–196 (1994).
  • Gamcsik MP , DolanME, AnderssonBS, MurrayD: Mechanisms of resistance to the toxicity of cyclophosphamide.Curr. Pharm. Des.5(8) , 587–605 (1999).
  • Shulman-Roskes EM , NoeDA, GamcsikMP et al.: The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and p–n bond hydrolysis reactions.J. Med. Chem.41(4) , 515–529 (1998).
  • Cai Y , WuMH, LudemanSM, GrdinaDJ, DolanME: Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.Cancer Res.59(13) , 3059–3063 (1999).
  • Andersson BS , SadeghiT, SicilianoMJ, LegerskiR, MurrayD: Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs.Cancer Chemother. Pharmacol.38(5) , 406–416 (1996).
  • Qiu R , KalhornTF, SlatteryJT: ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat.J. Pharmacol. Exp. Ther.308(3) , 1204–1212 (2004).
  • Huang Z , RoyP, WaxmanDJ: Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.Biochem. Pharmacol.59(8) , 961–972 (2000).
  • Lang T , KleinK, FischerJ et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.Pharmacogenetics11(5) , 399–415 (2001).
  • Takada K , ArefayeneM, DestaZ et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Arthritis Rheum.50(7) , 2202–2210 (2004).
  • Rocha V , PorcherR, FernandesJF et al.: Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after hla-identical sibling hematopoietic stem cell transplantation for patients with leukemia.Leukemia23(3) , 545–556 (2009).
  • Flockhart DA , RaeJM: Cytochrome P450 3A pharmacogenetics: the road that needs traveled.Pharmacogenomics. J.3(1) , 3–5 (2003).
  • Lamba JK , LinYS, ThummelK et al.: Common allelic variants of cytochrome p4503a4 and their prevalence in different populations.Pharmacogenetics12(2) , 121–132 (2002).
  • Spurdle AB , GoodwinB, HodgsonE et al.: The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.Pharmacogenetics12(5) , 355–366 (2002).
  • Gervot L , RochatB, GautierJC et al.: Human CYP2B6: expression, inducibility and catalytic activities.Pharmacogenetics9(3) , 295–306 (1999).
  • Su HI , SammelMD, VeldersL et al.: Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.Fertil. Steril. (2009) (Epub ahead of print).
  • Amirimani B , NingB, DeitzAC, WeberBL, KadlubarFF, RebbeckTR: Increased transcriptional activity of the CYP3A4*1B promoter variant.Environ. Mol. Mutagen.42(4) , 299–305 (2003).
  • Amirimani B , WalkerAH, WeberBL, RebbeckTR: Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.J. Natl Cancer Inst.91(18) , 1588–1590 (1999).
  • Ali-Osman F , AkandeO, AntounG, MaoJX, BuolamwiniJ: Molecular cloning, characterization, and expression in Escherichia coli of full-length cdnas of three human glutathione S-transferase π gene variants. Evidence for differential catalytic activity of the encoded proteins.J. Biol. Chem.272(15) , 10004–10012 (1997).
  • Hu X , HerzogC, ZimniakP, SinghSV: Differential protection against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage in HEPG2 cells stably transfected with allelic variants of π class human glutathione S-transferase.Cancer Res.59(10) , 2358–2362 (1999).
  • Hu X , XiaH, SrivastavaSK et al.: Activity of four allelic forms of glutathione s-transferase hgstp1–1 for diol epoxides of polycyclic aromatic hydrocarbons.Biochem. Biophys. Res. Commun.238(2) , 397–402 (1997).
  • Pandya U , SrivastavaSK, SinghalSS et al.: Activity of allelic variants of π class human glutathione s-transferase toward chlorambucil.Biochem. Biophys. Res. Commun.278(1) , 258–262 (2000).
  • Srivastava SK , SinghalSS, HuX, AwasthiYC, ZimniakP, SinghSV: Differential catalytic efficiency of allelic variants of human glutathione s-transferase π in catalyzing the glutathione conjugation of thiotepa.Arch. Biochem. Biophys.366(1) , 89–94 (1999).
  • Watson MA , StewartRK, SmithGB, MasseyTE, BellDA: Human glutathione s-transferase p1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.Carcinogenesis19(2) , 275–280 (1998).
  • Stanulla M , SchrappeM, BrechlinAM, ZimmermannM, WelteK: Polymorphisms within glutathione s-transferase genes (gstm1, gstt1, gstp1) and risk of relapse in childhood b-cell precursor acute lymphoblastic leukemia: a case–control study.Blood95(4) , 1222–1228 (2000).
  • Perera FP : Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention.J. Natl Cancer Inst.88(8) , 496–509 (1996).
  • Perera FP : Molecular epidemiology: on the path to prevention?J. Natl Cancer Inst.92(8) , 602–612 (2000).
  • Wilson JF , WealeME, SmithAC et al.: Population genetic structure of variable drug response.Nat. Genet.29(3) , 265–269 (2001).
  • Tew KD : Glutathione-associated enzymes in anticancer drug resistance.Cancer Res.54(16) , 4313–4320 (1994).
  • Hall AG , AutzenP, CattanAR et al.: Expression of µ class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia.Cancer Res.54(20) , 5251–5254 (1994).
  • Anderer G , SchrappeM, BrechlinAM et al.: Polymorphisms within glutathione s-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.Pharmacogenetics10(8) , 715–726 (2000).
  • Choi JY , NowellSA, BlancoJG, AmbrosoneCB: The role of genetic variability in drug metabolism pathways in breast cancer prognosis.Pharmacogenomics7(4) , 613–624 (2006).
  • Forrester LM , HayesJD, MillisR et al.: Expression of glutathione S-transferases and cytochrome p450 in normal and tumor breast tissue.Carcinogenesis11(12) , 2163–2170 (1990).
  • Dirven HA , van Ommen B, van Bladeren PJ: Involvement of human glutathione s-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res.54(23) , 6215–6220 (1994).
  • Rossi D , RasiS, FranceschettiS et al.: Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large b-cell lymphoma treated with R-CHOP21.Leukemia23(6) , 1118–1126 (2009).
  • Guy CA , HoogendoornB, SmithSK, ColemanS, O‘DonovanMC, BucklandPR: Promoter polymorphisms in glutathione-s-transferase genes affect transcription.Pharmacogenetics14(1) , 45–51 (2004).
  • Kusama M , KubotaT, MatsukuraY et al.: Influence of glutathione S-transferase a1 polymorphism on the pharmacokinetics of busulfan.Clin. Chim. Acta368(1–2) , 93–98 (2006).
  • Sweeney C , AmbrosoneCB, JosephL et al.: Association between a glutathione s-transferase a1 promoter polymorphism and survival after breast cancer treatment.Int. J. Cancer103(6) , 810–814 (2003).
  • Seidegard J , VorachekWR, PeroRW, PearsonWR: Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.Proc. Natl Acad. Sci. USA85(19) , 7293–7297 (1988).
  • Pemble S , SchroederKR, SpencerSR et al.: Human glutathione s-transferase theta (gstt1): cdna cloning and the characterization of a genetic polymorphism.Biochem. J.300(Pt 1) , 271–276 (1994).
  • Rebbeck TR : Molecular epidemiology of the human glutathione S-transferase genotypes gstm1 and gstt1 in cancer susceptibility.Cancer Epidemiol. Biomarkers Prev.6(9) , 733–743 (1997).
  • Hohaus S , MassiniG, D‘aloF et al.: Association between glutathione S-transferase genotypes and hodgkin‘s lymphoma risk and prognosis.Clin. Cancer Res.9(9) , 3435–3440 (2003).
  • Barahmani N , CarpentieriS, LiXN et al.: Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.Neuro. Oncol.11(3) , 292–300 (2009).
  • De Jonge ME , HuitemaAD, RodenhuisS, BeijnenJH: Clinical pharmacokinetics of cyclophosphamide.Clin. Pharmacokinet.44(11) , 1135–1164 (2005).
  • Yang G , ShuXO, RuanZX et al.: Genetic polymorphisms in glutathione-S-transferase genes (gstm1, gstt1, gstp1) and survival after chemotherapy for invasive breast carcinoma.Cancer103(1) , 52–58 (2005).
  • Sweeney C , McclureGY, FaresMY et al.: Association between survival after treatment for breast cancer and glutathione S-transferase p1 Ile105Val polymorphism.Cancer Res.60(20) , 5621–5624 (2000).
  • Hohaus S , Di Ruscio A, Di Febo A et al.: Glutathione S-transferase p1 genotype and prognosis in hodgkin‘s lymphoma. Clin. Cancer Res.11(6) , 2175–2179 (2005).
  • Dasgupta RK , AdamsonPJ, DaviesFE et al.: Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.Blood102(7) , 2345–2350 (2003).
  • Zhong S , HuangM, YangX et al.: Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.Br. J. Clin. Pharmacol.62(4) , 457–472 (2006).
  • Allan JM , WildCP, RollinsonS et al.: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.Proc. Natl Acad. Sci. USA98(20) , 11592–11597 (2001).
  • Sladek NE : Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.Curr. Pharm. Des.5(8) , 607–625 (1999).
  • Spence JP , LiangT, ErikssonCJ et al.: Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations.Alcohol Clin. Exp. Res.27(9) , 1389–1394 (2003).
  • Vasiliou V , PappaA: Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease.Pharmacology61(3) , 192–198 (2000).
  • Ekhart C , RodenhuisS, SmitsPH, BeijnenJH, HuitemaAD: Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.Pharmacogenet. Genomics18(11) , 1009–1015 (2008).
  • Vasiliou V , PappaA, PetersenDR: Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism.Chem. Biol. Interact.129(1–2) , 1–19 (2000).
  • Petros WP , HopkinsPJ, SpruillS et al.: Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.J. Clin. Oncol.23(25) , 6117–6125 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.